It's a delicate issue in more ways than one, Tabitha M. Powledge writes, citing a Nature commentary. How should regulators deal with the odd-sounding but apparently very effective practice of transplanting fecal material from healthy patients to sick ones? "The researchers propose that FDA look upon the feces used in transplants not as a new drug but rather as a tissue product. Or perhaps FDA should even devise a new classification, as the agency has done for blood."
